Introduction
Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia in old age affecting over 40 million people worldwide [1] . There are currently no therapies to prevent or slow AD progression, highlighting our incomplete knowledge of disease mechanisms and the need for new drug targets. A large number of biochemical processes are affected in AD and genes implicated in AD highlight the possible roles for lipid processing, immune function, phagocytosis, (innate) immunity and neurotransmitter function, biological pathways that may affect metabolism [2, 3] . Recent AD hypotheses implicate viral and bacterial contributions to disease pathogenesis [4] [5] [6] .
Bidirectional biochemical communication between the brain and the gut contribute to a variety of neurodegenerative and psychiatric diseases [7] [8] [9] [10] . The gut microbiome and the host collaboratively produce a large array of small molecules that impacts human health [11, 12] .
Recently, a role for the gut microbiome in motor dysfunction in Parkinson's disease has been highlighted [13] and several animal models of AD showed a possible role of gut bacteria in amyloid-beta (A) pathology [14, 15] . The APP transgenic mouse model of AD had a drastically altered gut microbiome composition compared to wild-type mice [15] . Other studies linked proinflammatory bacteria, such as gram-negative producers of neurotoxic lipopolysaccharides, to brain amyloidosis and systemic inflammation, a central feature of AD [16, 17] . These studies suggest microbial dysbiosis or imbalance could potentially contribute to AD pathogenesis.
Cholesterol metabolism in the liver is thought to play a key role in AD [18] . In fact, many cholesterol metabolism genes (e.g., BIN1, CLU, PICALM, ABCA7, ABCG1, and SORL1) are among the top AD susceptibility loci identified by genome-wide association studies [2, 19] .
Cholesterol is cleared through production of bile acids (BAs). Primary BAs, chenodeoxycholic acid (CDCA) and cholic acid (CA), are synthesized from cholesterol in the liver, conjugated with glycine or taurine, secreted into the gallbladder via the bile salt export pump (BSEP), and transported to the intestine to be metabolized by gut bacteria (Fig. 1) . Intestinal anaerobic bacteria deconjugate the liver-derived BAs through the action of bile salt hydrolases (BSH) to their respective free BAs. Subsequently, anaerobe bacteria convert primary BAs to the secondary BAs. That is, CA is converted to deoxycholic acid (DCA). CDCA is converted to lithocholic acid (LCA) and ursodeoxycholic (UDCA) through 7α or 7β -dehydroxylation, respectively [20, 21] .
In the terminal ileum and colon, BAs are reabsorbed by the enterocytes and released into the 6 portal vein for return to the liver where they are conjugated to produce their glycine and taurine forms.
Beyond BAs role in cholesterol clearance, BAs are major regulators for maintaining energy homeostasis through binding to nuclear receptors, including FXR, among others. BAs also modulate the gut microbiome [22, 23] . Both primary and secondary BAs are present in the brains of mice and humans with evidence that they cross the blood-brain barrier [24] [25] [26] [27] [28] [29] . Some BAs such UDCA exert beneficial effects while others are known to be cytotoxic [30] [31] [32] [33] [34] . In particular, DCA's toxicity has been associated with modulating apoptosis involving mitochondrial pathways in a variety of tissues and cell types [35] [36] [37] .
In recent pilot human studies, BA profiles were shown to be affected in AD [26, [38] [39] [40] .
Here, we used a targeted metabolomics approach to evaluate BA profiles in a large cohort of 1,464 individuals enrolled in the AD Neuroimaging Initiative (ADNI) where rich clinical, imaging, and genetic data exist. We used this data to address the following:
1. Investigate if BA profiles are altered in MCI and AD patients and if these differences are related to cognitive decline.
2.
Use ratios of BAs to pinpoint possible enzymatic alterations in the liver and in the gut microbiome that directly contribute to altered BA profile.
3.
Investigate whether immune related AD genome-wide significant genes affect levels of BAs in circulation as markers for altered gut microbiome function.
In a subsequent paper we evaluated correlations between BAs and ATN biomarkers of AD including CSF biomarkers, atrophy, and brain glucose metabolism. The ROS/MAP studies are both longitudinal cohort studies of aging and AD at Rush University, and are designed to be used in joint analyses to maximize sample size. ROS enrolled individuals from religious orders (nuns, priests, brothers) across the United States [41] . MAP was designed to complement the ROS study by using a similar structure and design as ROS, but enrolling participants with a wider range of life experiences and socioeconomic status from the Chicago, IL metropolitan area [42] . The entire ROS/MAP cohort consists of approximately 3,300 participants, more than 1,500 of whom have come to autopsy (www.radc.rush.edu). We measured a subset of serum BAs in 566 subjects (446 CN, 109 MCI, and 11 AD), as well as a subset of BAs in postmortem brain samples of 111 subjects with brain pathology performed (51 CN, 31 MCI, and 27 AD at time of death), of whom 93 also had serum measurements. Key demographic variables of ROS/MAP cohort are listed in Supplementary Table 1 .
Methods

Study cohorts and samples
Rotterdam study (RS)
RS was used to perform association of BAs with AD genetic variants. RS is a prospective population based study [43] . At the baseline examination in 1990-93, 7983 subjects ≥ 55 years of age were recruited from the Ommoord district of Rotterdam (RS-I). All the study participants were extensively interviewed and physically examined at baseline and after every 3 to 4 years.
During 2000 to 2001, the baseline cohort (RS-I) was expanded with 3011 subjects ≥55 years of age, who were not yet part of RS-I (RS-II). In this analysis, fasting serum BAs were measured for 488 dementia-free subjects with mean(SD) age of 73.1(6.3) from RS-I using Metabolon platform (Durham, North Carolina, USA) as described previously [44] (see Supplementary   Table 2 for demographics).
Sample collection and quantification of BAs
Targeted metabolomics profiling was performed to measure concentrations of 20 BA metabolites in serum samples of the ADNI cohorts (see Table 2 for list of BAs and abbreviations). Morning fasting serum samples from the baseline visit were collected and aliquoted as described in the ADNI standard operating procedures. BA quantification was performed by liquid chromatography tandem mass spectrometry using the Biocrates ® Life Sciences Bile Acids Kit (BIOCRATES Life Science AG, Innsbruck, Austria) according to manufacturer's instructions.
In the ROS/MAP, quantification of BA concentration in 566 serum samples and 111 postmortem brain samples was performed at the University of Hawaii cancer center using ultraperformance liquid chromatography coupled to a tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA) [45] .
In the RS study, serum BAs were measured in 488 serum samples using the non-targeted Metabolon platform (Durham, North Carolina, USA).
Quality control of BA profiles
Metabolomics lab staff were blinded to diagnosis and pathological data in all the studies.
In ADNI, after unblinding and data release, metabolite profiles went through quality-control (QC) checks and data preprocessing including batch-effect adjustment, missing value imputation, and log-transformation (Supplementary Methods and Supplementary Table 3 ). After QC correction, the dataset included 15 BAs (5 BAs did not pass QC criteria) for a total of 1,464 subjects (after excluding 99 SMC). The preprocessed BA values after QC were used for subsequent association analyses directly or were adjusted to take into account the effect of medications on BA levels [46] . The list of medications selected for adjustment for each BA is shown in Supplementary Table 7 . We performed all analyses using both medication adjusted and unadjusted BA levels, results derived from medication-adjusted data and the adjustment process are described in Supplementary Methods and its accompanying tables.
In both RS and ROS/MAP, missing metabolite levels were imputed using half of the limit of detection. Log-transformed values were used in subsequent analyses.
Clinical Outcomes
For ADNI data, continuous response variables included the modified Alzheimer Disease Assessment Scale 13-item cognitive subscale (ADAS-Cog13; range, 0 [best] to 85 [worst] points), an index of general cognitive functioning. Categorical response variables included clinical diagnosis at baseline and MCI conversion (MCI-NonConverter, MCI-Converter). For the ROS/MAP cohort, cognition was measured using a battery of tests (details are published [47] [48] [49] [50] ). A composite measure of global cognition was created by averaging the z-scores of all tests as previously described [50] . Mean and standard deviation at baseline were used to compute zscores. A negative z-score means that an individual has an overall score that is lower than the average of the entire sample at baseline. Cognitive tests were used from the same cycle as serum, and proximate to death for brain. Genotype exclusion criteria further included call rate < 95%, Hardy-Weinberg equilibrium p < 1.0x10 -6 and Minor Allele Frequency (MAF) < 1%. Genetic variants were imputed to the Haplotype Reference Consortium (HRC) reference panel (version 1.0) [52] using the Michigan imputation server [53] .
Genotype and whole genome sequencing data
Reference genetic associations with BA profiles in healthy individuals were obtained from supplementary data of the atlas of genetic influences on blood metabolites [44] . To obtain genome-wide genetic associations with DCA, we considered all suggestive significant results with P < 1.0 x 10 -5 . Gene and complex trait annotations of the 13 resulting genetic loci were performed using the SNiPA tool v3.2 [54] and the NHGRI-EBI Catalog of published genomewide association studies (www.ebi.ac.uk/gwas; accessed 02/01/2018, version 1.0) [55] . Lookup of AD genetic associations for DCA candidate variants was performed using the IGAP repository[2].
Statistical analysis
Differences of demographic, clinical, and cognitive measurements among the clinical diagnostic groups were evaluated using 2-sample t-test (for continuous variables) and Pearson Chi-squared test (for categorical variables). All analyses were performed in a metabolite-wise manner and Bonferroni-adjusted critical values were used to assess statistical significance. All models included age at baseline, sex, APOE ε4, and log10-transformed body mass index (BMI).
For cognition, number of years of education was added as an additional covariate.
Separate binary logistic regression models were conducted to examine cross-sectional association of each metabolite with baseline diagnosis (6 models per metabolite). We performed logistic regression models to compare BA levels between the MCI-NonConverter and MCI-Converter groups. Cox proportional hazard models were used to evaluate the association of metabolite levels with progression from MCI (combined EMCI and LMCI subjects) to AD. The cross-sectional association of ADAS-Cog13 with BAs was assessed using linear regression models with square root of ADS-Cog13 as the dependent variable.
In ROS/MAP, one sample per individual was used. Linear regression models with global cognition score as dependent variable and metabolites as independent variables were used to assess the association of serum BAs with cognition, while adjusting for sex, age, APOE ε4, and years of education. Similar analyses were conducted for brain BAs separately.
We restricted our genetic variant analysis to single nucleotide polymorphisms (SNPs) in genes involved in immune response pathway that were significantly associated with AD genomewide [2, [56] [57] [58] . Selected genetic variant included rs616338-T(ABI3), rs143332484-T(TREM2),
rs11771145-G(EPHA1), rs983392-A(MS4A6A), and rs190982 -A(MEF2C). Associations of AD risk variants in immune-related genes with selected metabolic traits in ADNI and RS were computed using sex, age, and BMI as covariates.
Results
Characteristics of ADNI participants are depicted in Table 1 . Baseline cognitive measurements were significantly different among diagnostic groups, as expected. AD patients were more often carriers of at least one APOE ε4 allele. In addition, ADAS-Cog13 scores were not significantly different between the MCI-converter and NonConverter groups. However, the proportion of APOE ε4 carriers was higher in MCI-Converter group.
Serum BA profiles are significantly altered in AD
The Bonferroni-corrected threshold for statistical significance was determined as P < 4.76
x 10 -4 (0.05 divided by 15 metabolites times 7 phenotypes including cognition). When we compared BA profile in AD to CN, we detected a significant decrease in levels of the primary BA, CA (P = 1.56 x 10 -4 ). In contrast, a significant increase of bacterially produced secondary BA, DCA was noted (P = 1.61 x 10 -4 ) along with several secondary conjugated BAs, GDCA, TDCA, and GLCA ( Table 2 ). GDCA and GLCA were significantly associated with ADAS-Cog13 where higher levels indicate worse cognition. Comparing BA levels between AD and both MCI groups yielded similar results, while the comparison of BA levels between the CN and MCI groups did not reach statistical significance ( Supplementary Table 4 ).
Ratios reflective of conversion of BAs by gut microbiome are significantly associated with AD and cognitive performance
To determine which enzymatic processes in BA metabolism may underlie the differences noted in AD, we investigated eight selected ratios reflective of enzymatic activities in the liver and the gut microbiome. These ratios included:
1. The CA:CDCA ratio was selected to test if a possible shift in BA synthesis from the primary to the alternative BA pathway occurs in the liver.
2.
Ratios of secondary to primary BAs (DCA:CA, GLCA:CDCA, and TLCA:CDCA) to investigate differences in gut microbiome enzymatic activity leading to altered production of secondary BAs. Since LCA was excluded in QC steps, the GLCA:CDCA and TLCA:CDCA ratios were used as proxies for LCA:CDCA ratio.
3. GDCA:DCA and TDCA:DCA ratios were used to test if the observed secondary BA dysregulation is related to enzymatic differences related to their taurine and glycine conjugation.
Here, we considered associations as significant at a Bonferroni-corrected P < 3.11 x 10 -4 (0.05 divided by all 23 metabolic traits times 7 phenotypes, which include cognition). The ratio of the primary BAs (CA:CDCA) showed no significant association with AD. Yet, for the ratio of DCA:CA, i.e. the conversion of unconjugated primary to unconjugated secondary BA, we observed a highly significant association with AD diagnosis (P=1.53 x 10 -8 ). Ratios between primary and secondary conjugated BAs showed the same effect and direction, including GDCA:CA (P=8.53 x 10 -10 ), TDCA:CA (P=9.83 x 10 -7 ), and GLCA:CDCA (P=3.61 x 10 -6 ).
Ratios modeling the glycine and taurine conjugation step of DCA, i.e. GDCA:DCA, TDCA:DCA, were not significantly associated with diagnosis ( Fig. 2 and Table 3 ).
Four ratios (including DCA:CA and GLCA:CDCA) were significantly associated with ADAS-Cog13. For the ratios we observed the same pattern as for AD diagnosis, with higher ratios of secondary to primary BAs being highly significantly associated with worse cognitive performance, while neither conjugation, nor a shift between primary and alternative BA pathways in the liver were significantly linked to cognition ( Table 2 and 3).
Serum BA levels were associated with progression from MCI to AD in ADNI
The 9 metabolites and ratios associated with diagnosis were further investigated to assess their relationship with progression from MCI to AD. Out of 779 MCI (EMCI and LMCI) patients with mean (SD) follow-up 3.94 (2.35), 32.2% progressed to AD dementia in four years (labeled as MCI-Converter (n=251) vs. those that did not progressed MCI-NonConverter (n=528)). BA profiles were compared between the two groups using logistic regression models with conversion status as dependent variable and metabolite as independent variable. Models were adjusted for age, sex, BMI, baseline ADAS-Cog13 score, and APOE ε4. The Bonferroni-corrected threshold for statistical significance was determined as P < 5.56 x 10 -3 (0.05 divided by 9 metabolites and ratios). We noted a decrease in CA levels (P=9.12 x 10 -4 ) and an increase in ratios of GDCA:CA (P=1.63 x 10 -3 ) and TDCA:CA (P=1.72 x 10 -3 ) in MCI-Converters ( Fig. 3 and Supplementary   Table 5 ). Further survival analysis also revealed that levels of CA (hazard ratio (HR), 0.92; P =3.79 x 10 -3 ), GDCA:CA (HR, 1.07; P=2.81 x 10 -3 ), and TDCA:CA (HR, 1.06; P=3.19 x 10 -3 ) ratios predicted MCI progression ( Fig. 3 ).
Replication of association between cognition and DCA:CA ratio in serum and brain from ROS/MAP
In order to confirm the associations observed in ADNI, we used an independent cohort of older adults (ROS/MAP) with measures of BAs in serum and brain to replicate our findings.
Since the sample sizes in ROS/MAP were smaller than ADNI and AD cases were strongly underrepresented (n=11 for the serum samples), we focused on replicating the association between global cognition (where higher values indicate better cognition, which is in contrast to ADNI where higher scores indicate worse cognition) and the DCA:CA ratio (as proxy for BA processing by the gut microbiome). Separate linear regression models were used for brain and serum samples. Pearson's correlation coefficient between serum DCA:CA and DCA:CA in 93 matching brain samples was 0.303 (P=0.003). In both serum and brain samples, higher levels of DCA:CA were associated with worse cognition (serum: β = -0.06; P = 0.011; brain: β = -0.21; P = 0.032), replicating our ADNI finding.
Genetic risk variants for AD in genes related to immune function are associated with bile acid levels
To further evaluate that altered BA profiles in AD are related to processes in the gut microbiome, we investigated if BA profiles were associated with immune-related AD risk genes which may contribute to differences in gut microbiome composition. Using the ADNI (n=817 with WGS data) and RS (n=488) cohorts, association of selected BAs in the primary BA pathway (CA, DCA, GDCA, and TDCA) as well as the DCA:CA ratio with the selected genetic risk variants in 9 candidate genes with immune-related functions was assessed. In addition, we included associations from a published large cohort-based study [44] to increase sample size.
With the exception of rs983392 in MS4A6A, we found nominally significant associations for the candidate variants in all of these genes ( Supplementary Table 10 ). Three associations were significant after Bonferroni-correction (P < 1.1 x 10 -3 ) in at least one of the studies: rs616338 (ABI3) and rs190982 (MEF2C) were significantly associated with the DCA:CA ratio, and rs11771145 (EPHA1) was significantly linked to both DCA and TDCA.
Genetic loci associated with DCA may influence susceptibility for AD
To follow up on the hypothesis that elevated DCA levels in AD linked to gut dysbiosis are relevant in the pathogenesis of AD, we collected (suggestive) significant genetic associations with DCA levels (P < 1.0 x 10 -5 ) from a previous study of genetic influences on blood metabolite levels in large population-based cohorts (n~7,800) [44] . We then annotated the resulting 13 loci with genetic trait associations, including AD associations from the IGAP study [2] , and tried to replicate associations with DCA in ADNI ( Supplementary Table 11 ).
Two of the 13 genes, CYP7A1 and IMPA2, also showed association with DCA levels in ADNI subjects. Notably, six of the 13 genes have been previously linked via genetic studies to AD (ABCA7) or AD phenotypes, including cognitive decline and CSF protein levels (LRRC7, CYCS, GPC6, FOXN3 and CNTNAP4).
Discussion
Cholesterol metabolism has been extensively implicated in the pathogenesis of AD through biological, epidemiological, and genetic studies, yet the molecular mechanisms linking cholesterol and AD pathology are still not well understood. Many cholesterol metabolism related genes such as BIN1, CLU, PICALM, ABCA7, ABCG1, and SORL1 are classified among the top 20 late onset AD susceptibility loci by some of the largest genome-wide association studies (GWAS) undertaken to date [2, 19] . The ε4 allele of the apolipoprotein gene [59, 60] , the most robust and reproducible genetic risk factor for AD, is involved in the transport of cholesterol.
In this study, we interrogated a possible role for BA end products of cholesterol metabolism and clearance in cognitive changes in AD. BA are produced in liver and by the gut microbiome, provide key regulatory functions in energy homeostatic mechanisms, and are indicators of gut dysbiosis. Using stored blood samples from ADNI studies we established that BA profile is significantly altered in AD patients with changes detected earlier in disease ( Fig. 1 and 2) . We noted a significant decrease in serum levels of a liver-derived primary BA (CA) and an increase in levels of a bacterially produced secondary BAs and their conjugated forms (DCA, GDCA and TDCA, GLCA) in AD patients compared to cognitively normal subjects ( Table 2 , Fig. 1A ).
Higher levels of secondary conjugated BAs (GDCA, GLCA, and TLCA) were significantly associated with worse cognitive function measured by the ADAS-Cog13 ( Table 2 , Fig. 1A) .
To inform about enzymatic activity changes in liver and gut, three types of metabolite ratios were evaluated to inform about mechanisms leading to the noted altered BA profile in AD. We found no shift in metabolism between primary and alternative pathways ( Fig. 2 ; no change in CA:CDCA); a significant change in production of secondary BAs via enzymatic activities in gut microbiome (increased DCA:CA as well as GLCA:CDCA and TLCA:CDCA as proxies for LCA:CDCA) and no change in processes involved in glycine and taurine conjugation of secondary BAs in the liver (no change in GDCA:DCA and TDCA:DCA). The significant increase in ratios of secondary to primary BAs (e.g. DCA:CA; Fig. 2) , suggest altered activity of bacterial 7α-dehydroxylases leading to excess production of secondary BAs many of which were previously reported as cytotoxic [34, [61] [62] [63] . This indicates potential gut dysbiosis in AD patients possibly caused by enhanced colonization of the large and possibly the small intestine with anaerobic bacteria capable of CA and CDCA 7α-dehydroxylation. Increases in these ratios also significantly correlated with poorer cognition ( Table 2) . Together, these findings suggest that enzymatic steps in conversion of primary to secondary BAs in the gut might contribute to disease.
We also evaluated effects of BA levels on risk of progression to AD among 538 MCI patients. We noted that lower levels of CA and higher ratio of secondary to primary BAs, GDCA:CA, and TDCA:CA were significantly associated with risk of developing AD dementia ( Fig. 3, Supplementary Table 6 ).
The increased production of bacterially produced DCA from CA modeled by ratio DCA:CA and its link to cognition was replicated in the independent ROS/MAP cohort. Association of the DCA:CA ratio with disease severity was evaluated separately in serum and brain samples. Due to the small number of AD patients (n=11), we used global cognitive score as an index of disease severity. Similar to ADNI findings, an increase in the DCA:CA in both serum and brain were significantly associated with worse cognitive outcome. This finding suggests that downstream effects of the gut-directed dysregulation of primary vs. secondary BAs are not limited to the periphery, but also might affect metabolic homeostasis and/or signaling functions in the human brain.
Earlier smaller studies suggested differences in BA levels in AD [26, [38] [39] [40] . For example, in a study of 495 plasma metabolites comparing metabolite levels among MCI (n=58) and AD (n = 100) with those of cognitively normal controls (n=93), levels of DCA, LCA, and GLCA were significantly elevated in the disease state [40] . Mapstone and colleagues [38] identified increased levels of glycoursodeoxycholic acid (GUDCA) in subjects likely to develop amnestic MCI or AD within the next 2 to 3 years compared to the control group. We replicated these findings with the exception of LCA that was excluded during QC and GUDCA, which showed only a nonsignificant trend of upregulation in the AD group (P = 0.054).
Composition and functional changes of the gut microbiome have been implicated in several diseases. Microbiome GWAS reveal that variants in many human genes involved in immunity and gut architecture are associated with an altered composition of the gut microbiome [64] .
Although many factors such as diet can affect the microbial organisms residing in the gut, emerging data support the hypothesis that certain host genetic variants predispose an individual towards microbiome dysbiosis and this can be linked to disorders of metabolism and immunity such as Crohn's disease, ulcerative colitis, type 2 diabetes mellitus, asthma, obesity, autism and rheumatoid arthritis [64] .
Accumulating evidence links dysregulation of the immune system to AD pathology. In particular, genetic association studies in AD have robustly identified several genetic risk variants in immune-related genes [2, 58] . Using the ADNI and RS cohorts, we investigated the association of BA profiles of CN subjects with genetic variants in nine AD-related and innate immunity genes. Eight of them were associated with selected BA levels at nominal significance (Supplementary Table 10 ). Three of these associations were significant after Bonferronicorrection, with rs616338 (ABI3) and rs190982 (MEF2C) associated with the DCA:CA ratio, and rs11771145 (EPHA1) linked to both DCA and TDCA. The association of the BAs to AD genes suggest that these immune related genes may influence the risk of AD through the BA metabolism or changes in the gut microbiome. Interestingly, both ABI3 and MEF2C are thought to be involved in immune reactions to pro-inflammatory stimuli that are partially secreted by microbes [65, 66] . The link to the DCA:CA ratio may thus mirror differences in gut microbiome composition due to altered immune response in AD, providing a mechanistic hypothesis for our findings. The function of EPHA1 is not well understood but, it has been hypothesized that when activated, this receptor may affect the integrity of the blood brain barrier (BBB) [67] . Its association with levels of DCA is intriguing as DCA is known to be cytotoxic and can disrupt the BBB and then enter the brain [28] . rs11771145 is associated with gene expression levels of EPHA1 [54] , and as DCA is not known to be produced by human metabolism, changed expression and activity of EPHA1 may be related to DCA-mediated cytotoxic effects.
Using an established atlas of genetic influences on human blood metabolites [44] , we further investigated a potential cytotoxic role of DCA. For almost half of the 13 identified loci, we found genetic evidence for involvement in AD-linked complex traits ( Supplementary Table   11 ). In particular, ABCA7 is an AD risk gene replicated in several genetic studies [68, 69] . Five additional genes (LRRC7, CYCS, GPC6, FOXN3, and CNTNAP4) genetically influence AD phenotypes, including cognitive decline and CSF markers. While it remains speculative if and how these genes interact with DCA to contribute to AD risk, it is intriguing that we identified ABCA7 by screening for associations with DCA levels. ABCA7 is highly expressed in the brain, and functions in the efflux of lipids, including cholesterol, from cells. Due to the structural similarity of DCA and cholesterol, we hypothesize that ABCA7 may be able to also transport this BA, reconciling metabolomics findings via a functional hypothesis to a risk gene for AD. The findings that BA levels are regulated by AD related genes might provide new mechanistic insights.
There is growing support for strong connections between the intestinal environment, with its diverse microbial composition and activity, and the functions of the central nervous system. The "gut-brain metabolic axis" facilitates bidirectional chemical communication between the central and enteric nervous systems through mechanisms just starting to be defined [7] [8] [9] . Such a metabolic axis is thought to be involved in the regulation of multiple host metabolic pathways in which levels of hormones, neurotransmitters, amines, GABA, short-chain fatty acids (SCFA), lipid metabolites, and others are regulated by gut microbiome activity [12] . Changes in the composition of intestinal bacterial populations are associated with a wide array of conditions, including neurological and neurodevelopmental disorders such as multiple sclerosis, autism, depression, schizophrenia, and Parkinson's disease [70] [71] [72] . In addition, increasing evidence suggest that liver disease may impact cognitive functions and contribute to AD [73] .
Our findings suggest novel metabolic links in AD where BAs represent a component of the gut-liver-brain axis that relates to cognitive functions. It is of interest that BAs that are ligands for the nuclear transcription factor FXR, which along with other nuclear receptors acts synergistically as metabolic sensors to regulate energy homeostasis pathways [74, 75] peripherally might also propagate their effects to the brain. Interestingly, levels of four BAs that are produced by the gut microbiome and that we show to be significantly correlated with disease status and cognition (DCA, GLCA, TLCA, TDCA) are hydrophobic and cytotoxic [34, 35, 76, 77] . Cell lines, animal models, and human studies suggest that levels of such BA, particularly DCA, lead to a disruption of mitochondrial membranes resulting in increased reactive oxygen species, markers of inflammation, and apoptosis as well as decreases in cell viability and DNA synthesis [34, 35, 78] . DCA increases BBB permeability with deuterium labelled DCA showing it crosses the BBB in rodents [27, 29] . Increased amounts of secondary BAs in blood may enter the brain through induced permeability of the BBB, affecting brain physiology and metabolism [28] .
Additionally, the BA nuclear receptor FXR, TGR5, and transporters Ostα/Ostβ seem to be expressed in the brain [79] . Several studies in human and animal brains also revealed that the full panel of BAs are found in the brain [24] [25] [26] [27] , but it is unclear whether this is due to transport from the periphery, from local synthesis, or both. The function of these BAs in the brain remains poorly defined with some support for them acting as neurosteroids [80] BA levels and the gut microbiome influence each other, where BSH-rich bacteria readily modify the BA profile while, on the other hand, intestinal BAs control the growth and maintenance of commensal bacteria, maintain barrier integrity, and modulate the immune system [81] [82] [83] [84] . Such changes might impact brain functions. Future longitudinal studies covering pre-symptomatic stages are needed to establish the influence of immune changes on gut microbiome composition and activity in AD patient. Tracking earliest changes in BA and other gut derived metabolites might provide insights into causality. Labeling studies are needed to evaluate if BAs cross the BBB and build up in brain with further elucidation of their signaling and regulatory functions centrally. However, we cannot exclude the possibility that changes in the brain during disease can also impact the gut and liver, and hence some of our findings might be brain derived.
Limitations
This is an observational study, the results of which may contain confounding biases. The impact of BAs on FXR, TGR5, vitamin, and hormone receptors in the brain and the signaling pathways impacted are currently unclear. It is important to evaluate in other large community studies the generalizability of our findings. The genetic links need to be tested in large populations.
Conclusions
In summary, there is evidence of a relationship among intestinal BA profile, gut microbial composition and/or activity, innate immunity, and genetic variants implicated in AD. An email with links to the Authorship Form will be sent to authors for completion after manuscripts have been submitted a Several ratios were calculated to inform about possible enzymatic activity changes in Alzheimer's patients. These ratios reflect: (1) Shift in bile acid metabolism from primary to alternative pathway. (2) Changes in gut microbiome correlated with production of secondary bile acids.
(3) Changes in glycine and taurine conjugation of secondary bile acids. b Outcome: Baseline diagnosis; Odds ratios and p-values were obtained from logistics regressions. Models were corrected for age, sex, body mass index, and APOE ε4 status; Bonferroni-adjusted critical value was set to 1.04E-03 based on 6 possible pairwise comparison of diagnosis groups (CN, EMCI, LMCI, and AD) for 8 ratios. c Outcome: Square root of ADASCog-13 (0 [best] to 85 [worst]); Models were corrected for age, sex, years of education, body mass index, and APOE ε4 status; Bonferroni-adjusted critical value was set to .11 x 10 -4 (0.05 divided by all 23 metabolic traits times 7 phenotypes, which include cognitive function). A and B. Lower levels of CA and higher levels of two secondary to primary ratios were significantly associated with higher odds of converting from MCI to AD. EMCI and LMCI patients that converted to AD dementia in 4 years after baseline were labeled as MCI-Converter; 9 bile acids and ratios that were significantly dysregulated between CN to AD were assessed; P-values were estimated from logistic regression models and adjusted for age, sex, body mass index, and APOE ε4 status; the significance level was adjusted for multiple testing according to Bonferroni 0.05/9 = 5.56 x 10 -3 . C and D. Cox hazards model of the association of conversion from MCI to AD. Red line: 1st quantile, Red line: 3rd quantile. Analysis was conducted using quantitative values and stratification by quantiles was used only for graphical representation.
